Navigation Links
Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
Date:11/19/2008

TSX: BMR

TORONTO, Nov. 19 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it will be presenting an abstract on the Phase II data from Neuradiab(TM) at the Society for Neuro-Oncology's (SNO) 13th Annual Scientific Meeting. The abstract, outlining the results from two previously conducted Phase II trials, is titled An update on the effects of Neuradiab(TM) on Patients with Newly Diagnosed Glioblastoma Multiforme (GBM). The SNO meeting is being held in Lake Las Vegas, Nevada from November 20th to 23rd at the Loews Lake Las Vegas Resort. The abstract will be presented between 5:00pm and 7:00pm on Saturday, November 22nd during the Meeting's General Poster Session.

The abstract describes the response of newly diagnosed GBM patients treated with Neuradiab as an adjunct to the current standard of care, consisting of surgery, temozolomide and external radiation. A recent analysis of study 01128 after 231 weeks of median follow-up (n = 14) showed a median overall survival of 102.1 weeks, and a median progression free survival of 77.3 weeks, or 17.8 months. Study 05018 showed a median overall survival of 107.7 weeks and a progression free survival of 74.6 weeks, or 17.2 months, (n = 5). The increase in overall survival and progression free survival will be presented in comparison to historical data from other third-party published trials. A copy of the abstract will be posted on the Company's website on November 23rd at www.bradmerpharma.com.

The analysis of the 231 week follow-up data was conducted after the submission and publication of the studies in Neuro-Oncology, reference:

Reardon et al., J Neuro-Oncology, Doc. D06-00199, February 20, 2008 or

http://neuro-oncolog
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bradmer announces 2008 third quarter operational and financial results
2. Bradmer to present at Rodman & Renshaw Healthcare Conference
3. Bradmer receives FDA approval to proceed with Phase III clinical trial
4. Bradmer announces 2008 first quarter operational and financial results
5. Bradmer announces new additions to management team
6. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
7. Notice of Bradmer Pharmaceuticals Conference Call
8. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
9. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
10. Bradmer announces additions to Scientific Advisory Board
11. Bradmer Medical Isotope Supply For Phase III Trial Secure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... According to a new market research report ... and Others), Devices (Power IC, Power Module & Power ... 2014 - 2020", the Power Electronics market is expected ... market is valued at $36.86 Billion and expected to ... The report also includes an in-depth analysis of the ...
(Date:7/14/2014)... SingaporeA*STAR,s Bioprocessing Technology Institute (BTI) has entered into ... pharmaceutical company, Roche, to identify novel drug candidates ... partnership brings together BTI,s capabilities in novel antibody ... (mAbs) therapeutics, opening up the possibility of ... death worldwide. , The collaboration makes use ...
(Date:7/14/2014)... Botanica Day Spa announced last month that ... at the day spa in down town Clearwater, FL ... other refreshments will be served as clients are invited ... products and great deals on spa services, including ... Dermaplaning (also known as “facial shaving”) is a simple ...
(Date:7/14/2014)... HealthDay Reporter SUNDAY, July ... a faltering sense of smell might signal the early ... smell test could spot who needs more extensive screening ... ability to identify odors was associated with the loss ... "We,re trying to be able to diagnose Alzheimer,s ...
(Date:7/14/2014)... Amy Norton HealthDay ... Older adults who enjoy mentally stimulating games may have bigger ... suggests. The study looked at the connection between playing ... acuity for adults in their 50s and 60s. Researchers ... other day performed better on tests of memory and other ...
Breaking Medicine News(10 mins):Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 3Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 4Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 5Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... a newborn baby going under the knife to repair a ... work begins for parents. University of Alberta nursing professor Gwen ... a former pediatric cardiology nurse; she wanted to find out ... per cent convinced that health-care professionals get what these parents ...
... 26 The Providence Service,Corporation (Nasdaq: PRSC ) ... financial advisor. , In ... strategic,options relating to, among other things, delevering its debt, growing ... UBS,Investment Bank has been retained in connection with selling certain,non-strategic ...
... Stylists, beauticians may be affected by phthalates in these ... -- Mothers exposed to a common hairspray chemical while ... born with an abnormally placed urinary opening, a new ... fragrances, and nail and hair products contain chemicals called ...
... are misaligned and point outward are at significantly ... adulthood, according to findings of a Mayo Clinic ... ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official journal of the ... examined the medical records of 407 patients with ...
... it,s cheaper and less time-consuming than in-person visits, study ... counseling may be as effective as face-to-face counseling in ... University of Florida study included 234 obese women, ages ... Florida. , All the women completed a six-month weight-loss ...
... Public engagement practitioners from across the world are to ... be held in South Africa, organised by the Wellcome ... engage to empower" will take place from 2-5 ... Studies, KwaZulu-Natal. It will bring together practitioners working in ...
Cached Medicine News:Health News:Parents are the unsung heroes 2Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
(Date:7/14/2014)... , 14 de julio de 2014 /PRNewswire-HISPANIC PR ... anunciar que Barry Epling , presidente de la ... CEO de la Compañía. El señor Epling es el ... que otorgó la licencia de su formulación, sus propiedades ... proveedor de apoyo financiero. "El señor ...
(Date:7/14/2014)... , July 14, 2014  Invivotek L.L.C., a ... pleased to announce that its animal research facility ... the Assessment and Accreditation of Laboratory Animal Care ... animals in science worldwide through voluntary accreditation and ... animal care and use in 38 countries. ...
(Date:7/14/2014)... July 14, 2014 Valeant Pharmaceuticals International, ... VRX) today announced it has filed a premerger ... 1976 (HSR) with the U.S. Federal Trade Commission ... Inc. (NYSE: AGN). About Valeant ... International, Inc. (NYSE/TSX: VRX) is a multinational specialty ...
Breaking Medicine Technology:BioAdaptives se prepara para el próximo paso 2BioAdaptives se prepara para el próximo paso 3Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5
... PCI program is critical, CHICAGO, March 29 ... and successfully in medical centers without,on-site cardiac surgical ... to quality. These are the findings of the,largest ... have on-site,cardiac surgery to PCI programs that transfer ...
... days and out to 450 days in patients who ... either bare metal or drug-eluting stents, CHICAGO, March 29 ... and highly,statistically significant reduction in the risk of coronary stent,thrombosis ... fatal consequences - in patients who received a stent as,compared ...
Cached Medicine Technology:Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery 2Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery 3Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery 4Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel 2Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel 3Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel 4Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel 5Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel 6Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel 7
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: